Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (ATRA)
NASDAQ:ATRA
ATRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.40 - $23.43
Previous CloseN/A
Volume32.09K
Average Volume (3M)341.20K
Market Cap
$49.48M
Enterprise Value$81.44M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Mar 03, 2025EPS Estimate
-2.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.66
Shares Outstanding5,759,750
10 Day Avg. Volume124,294
30 Day Avg. Volume341,203
Standard Deviation0.26
R-Squared0.00847
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.49
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-260.19
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$9.67Price Target Upside12.57% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Financial SupportAtara received a $15M equity line of credit from Redmile group, which should fund Ebvallo into BLA resubmission.
Manufacturing And Regulatory ProgressA second third-party manufacturer FUJIFILM Diosynth Biotechnologies (FDB) has recently been approved to manufacture Ebvallo for EMA, supporting the overall manufacturing process.
Potential Milestone PaymentsShould the FDA approve tab-cel, Atara will receive a $60M milestone payment from Pierre Fabre.
Bears Say
Financial PerformanceProjected full-year 2024 net loss is $16.63 per share vs. prior estimate of a net loss of $0.73 per share.
Regulatory ChallengesThe recent Complete Response Letter (CRL) for EBVALLO and the FDA's cessation of several trials linked to the rejection of the EBVALLO application.
Workforce ReductionAtara announced a reduction in its workforce that will impact approximately 50% of its current employees.
---
Ownership Overview
34.11% Insiders
7.35% Mutual Funds
21.94% Other Institutional Investors
33.35% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ATRA FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was $5.40 and its highest was $23.43 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Atara Biotherapeutics’s market cap is $49.48M.
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 14 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Nov 12, 2024. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$1.888 by -$1.042.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -2.76.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 5,759,750 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$2.93 in its last earnings report, missing expectations of -$1.888. Following the earnings report the stock price went up 22.194%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Among the largest hedge funds holding Atara Biotherapeutics’s share is Woodline Partners LP. It holds Atara Biotherapeutics’s shares valued at 0.
---
Atara Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.67 (12.57% Upside)
$9.67 (12.57% Upside)
Blogger Sentiment
Bullish
ATRA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 70.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $45.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.38%
12-Months-Change
Fundamentals
Return on Equity
1063.61%
Trailing 12-Months
Asset Growth
-24.41%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
---
ATRA Stock 12 Month Forecast
Average Price Target
$9.67
▲(12.57% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Cara Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering ATRA
1 Year
1 Year Success Rate
18/41 ratings generated profit
1 Year Average Return
+2.04%
reiterated a buy rating last month
Copying John Newman's trades and holding each position for 1 Year would result in 43.90% of your transactions generating a profit, with an average return of +2.04% per trade.
---